Table 2. Preferred switch when no inertia occurs (a) towards treatment class and (b) towards treatment type.
| a. Preferred switch towards angiotensine converting enzyme inhibitors and beta-blockers | |||||||||
| Preferred strategy treatment class | |||||||||
| N | After switch | ||||||||
| BB | CCB | ACEi | ARB | Thiazides-type | Thiazide-like | Other Diuretics | |||
| Before switch | BB | 807 | 90% | 19% | 89% | 5% | 8% | 9% | 2% |
| CCB | 459 | 40% | 72% | 85% | 11% | 8% | 27% | 3% | |
| ACEi | 773 | 53% | 42% | 97% | 2% | 3% | 26% | 2% | |
| ARB | 188 | 53% | 44% | 45% | 54% | 36% | 13% | 4% | |
| Thiazides-type | 183 | 70% | 35% | 78% | 16% | 28% | 20% | 1% | |
| Thiazide-like | 122 | 36% | 54% | 93% | 5% | 4% | 68% | 2% | |
| Diuretics other | 57 | 63% | 25% | 81% | 7% | 5% | 23% | 37% | |
Abbreviations: BB: beta-blocker; CCB: calcium channel blocker; ACEI: angiotensine converting enzyme inhibitor; ARB: angiotensin receptor blockers; SPC: single pill combination. SPC only = exclusive use of SPCs / SPC Plus = use of SPCs and single molecule antihypertensive drugs.